Document ID: FDA-2012-N-0001-0132
Agency: fda
Document Type: Notice
Title: Nonprescription Drugs Advisory Committee Meeting
Posted Date: 2012-10-19T04:00Z

[Federal Register Volume 77, Number 203 (Friday, October 19, 2012)]
[Notices]
[Pages 64346-64347]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-25788]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]

Nonprescription Drugs Advisory Committee; Amendment of Notice

AGENCY:  Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of meeting of the Nonprescription Drugs Advisory 
Committee. This meeting was announced in the Federal Register of August 
30, 2012 (77 FR 52743). The amendment is being made to reflect a change 
in the Location and Contact Person portions of the document. There are 
no other changes.

FOR FURTHER INFORMATION CONTACT:  Minh Doan, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Building 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001,

[[Page 64347]]

FAX: 301-847-8533, email: NDAC@fda.hhs.gov, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), and follow the prompts to the desired center or product area. 
Please call the Information Line for up-to-date information on this 
meeting.

SUPPLEMENTARY INFORMATION:  In the Federal Register of August 30, 2012, 
FDA announced that a meeting of the Nonprescription Drugs Advisory 
Committee would be held on November 9, 2012. On page 52743, in the 
third column, the Location portion of the document is changed to read 
as follows:
    Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 
31 Conference Center, the Great Room, (Rm. 1503), Silver Spring, MD 
20993-0002. Information regarding special accommodations due to a 
disability, visitor parking, and transportation may be accessed at: 
http://www.fda.gov/AdvisoryCommittees/default.htm; under the heading 
``Resources for You,'' click on ``Public Meetings at the FDA White Oak 
Campus.'' Please note that visitors to the White Oak Campus must enter 
through Building 1.
    On page 52743, in the third column, the Contact Person portion of 
the document is changed to read as follows:
    Contact Person: Minh Doan, Center for Drug Evaluation and Research, 
Food and Drug Administration, 10903 New Hampshire Ave., Building 31, 
Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-
8533, email: NDAC@fda.hhs.gov, or FDA Advisory Committee Information 
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A 
notice in the Federal Register about last minute modifications that 
impact a previously announced advisory committee meeting cannot always 
be published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: October 16, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-25788 Filed 10-18-12; 8:45 am]
BILLING CODE 4160-01-P